SCHEMBL80806

SCHEMBL80806

OCC#Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
CES2 O00748 1/20 0.39
IDO1 P14902 2/20 0.35
CCNB2 O95067 1/20 0.35
CDK1 P06493 1/20 0.35
CCNB1 P14635 1/20 0.35
CCNB3 Q8WWL7 1/20 0.35
MELK Q14680 1/20 0.35
P2RY6 Q15077 1/20 0.33
RXRA P19793 2/20 0.33
RXRG P48443 2/20 0.33
FFAR1 O14842 1/20 0.33
LMNA P02545 1/20 0.33
MMP2 P08253 1/20 0.33
MMP12 P39900 1/20 0.33
RXRB P28702 1/20 0.33
ADRB1 P08588 1/20 0.32
TAS2R14 Q9NYV8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18195376 0.87 ALDH1A1 (0.42) ALDH1A1GAAHTTCCNB2CDK1
SCHEMBL16829668 0.84 SHMT1 (0.40) ALDH1A1GAAHTTCES2IDO1
SCHEMBL1591331 0.81 FFAR1 (0.51) ALDH1A1GAAHTTCES2CCNB2
SCHEMBL31345011 0.81 SHMT1 (0.42) ALDH1A1GAAHTTCES2IDO1
SCHEMBL20568704 0.81 P2RY6 (0.42) ALDH1A1GAAHTTP2RY6LMNA
SCHEMBL22031535 0.80 ALDH1A1 (0.53) ALDH1A1GAAHTTIDO1CCNB2
SCHEMBL31098060 0.80 ALDH1A1 (0.53) ALDH1A1GAAHTTIDO1CCNB2
SCHEMBL1745119 0.79 KIF11 (0.44) ALDH1A1GAAHTTCES2CCNB2
SCHEMBL5894329 0.79 IDO1 (0.35) ALDH1A1GAAHTTCES2IDO1
SCHEMBL18195369 0.73 SHMT1 (0.41) ALDH1A1GAAHTTTAS2R14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3083642-B1 FUSED BICYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN MERCK SHARP & DOHME (US) 2018-09-05 EP disclosed
US-9663534-B2 Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein MERCK SHARP & DOHME CORP. (US) 2017-05-30 US disclosed
US-9663534-B2 Fused bicyclic isoxazolines as inhibitors of cholesterol ester transfer protein MERCK SHARP & DOHME CORP. (US) 2017-05-30 US disclosed
US-20160318950-A1 FUSED BICYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN MERCK SHARP & DOHME CORP. (US) 2016-11-03 US disclosed
US-20160318950-A1 FUSED BICYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN MERCK SHARP & DOHME CORP. (US) 2016-11-03 US disclosed
EP-3083642-A1 FUSED BICYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN Merck Sharp & Dohme Corp. (US) 2016-10-26 EP disclosed
EP-2168944-B1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2016-05-11 EP disclosed
WO-2015094932-A1 FUSED BICYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN MERCK SHARP & DOHME CORP. (US) 2015-06-25 WO disclosed
WO-2015094932-A1 FUSED BICYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN MERCK SHARP & DOHME CORP. (US) 2015-06-25 WO disclosed
US-8129361-B2 Amine compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-06 US disclosed
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-15 US disclosed
EP-2168944-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-03-31 EP disclosed
EP-0749430-B1 THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS AMERICAN HOME PROD (US) 1999-08-25 EP disclosed
US-5605918-A SUBSTITUTED THIAZOLIDINE-2,4-DIONES AMERICAN HOME PRODUCTS CORPORATION (US) 1997-02-25 US disclosed
EP-0749430-A1 THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1996-12-27 EP disclosed
US-5574051-A HYPOGLYCEMIC AMERICAN HOME PRODUCTS CORPORATION (US) 1996-11-12 US disclosed
WO-1995024400-A1 THIAZOLIDINEDIONE DERIVATIVES AS ANTI-HYPERGLYCEMIC AGENTS AMERICAN HOME PRODUCTS CORPORATION (US) 1995-09-14 WO disclosed
EP-0041324-B1 A NEW PHENYLPROPARGYLAMINE DERIVATIVE MAY & BAKER LIMITED (GB) 1983-06-08 EP disclosed
US-4347252-A Rodenticidal 1-(3,5-bistrifluoromethylphenyl)-3-(4-t-butylpiperidino)prop-1-yne MAY & BAKER LTD. (GB) 1982-08-31 US disclosed
EP-0041324-A1 A new phenylpropargylamine derivative MAY & BAKER LIMITED (GB) 1981-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318950-A1 FUSED BICYCLIC ISOXAZOLINES AS INHIBITORS OF CHOLESTEROL ESTER TRANSFER PROTEIN CETP, MTTP, LCAT ALDH1A1 3540/4885GAA 2302/4885HTT 3048/4885
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF HLA-B, HLA-A, HLA-C ALDH1A1 646/4885GAA 1918/4885HTT 3158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.